Nalaganje...
Golimumab pharmacokinetics in ulcerative colitis: a literature review
Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two...
Shranjeno v:
| izdano v: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330616/ https://ncbi.nlm.nih.gov/pubmed/28286562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16676194 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|